Pertussis is an endemic disease in the EU/EEA and worldwide. Every three to five years, larger epidemics are expected even with high vaccination coverage.
This report presents pooled COVID-19 vaccine effectiveness (VE) estimates for the first, second and third booster doses (compared to complete primary vaccination with no booster) against hospitalisation due to COVID-19 and COVID-19-related death in resident populations ≥50 years of age living in the community.
At the request of the Slovenian National Institute of Public Health (NIJZ), ECDC designed and facilitated an After-Action review (AAR), focusing on the response to the COVID-19 pandemic.
This document assesses the risk associated with the dissemination of carbapenemase-producing hypervirulent Klebsiella pneumoniae (hvKp) of sequence type (ST) 23 and other STs in the European Union/European Economic Area (EU/EEA).
Arenaviruses are a type of small virus commonly found in rodents. When a person becomes infected with an arenavirus, symptoms usually begin within 10 days.
ECDC initiated a survey of EU/EEA countries to evaluate preparedness planning and risk mitigation initiatives implemented at the country level for people exposed to highly pathogenic avian influenza virus A(H5N1).
The aim of this survey was to review the expertise, capabilities and capacities for detection and characterisation of avian and other zoonotic influenza viruses in national influenza reference laboratories in the European Union/European Economic Area (EU/EEA), in members of the European Reference Laboratories for influenza (ERLINet), and in EU Enlargement policy countries.
This report presents pooled COVID-19 vaccine effectiveness (VE) estimates for the first, second and third booster doses, against hospitalisation due to COVID-19 and COVID-19 related deaths in resident populations ≥50 years of age, living in the community.